Cullinan Therapeutics, Inc. (CGEM)
11.31
+0.51
(+4.72%)
USD |
NASDAQ |
Nov 06, 16:00
11.29
-0.02
(-0.18%)
After-Hours: 20:00
Cullinan Therapeutics Research and Development Expense (Quarterly) : 44.44M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 44.44M |
| March 31, 2026 | 42.12M |
| December 31, 2025 | 42.94M |
| September 30, 2025 | 41.97M |
| June 30, 2025 | 61.03M |
| March 31, 2025 | 41.46M |
| December 31, 2024 | 40.49M |
| September 30, 2024 | 35.51M |
| June 30, 2024 | 36.26M |
| March 31, 2024 | 30.65M |
| December 31, 2023 | 34.85M |
| September 30, 2023 | 33.82M |
| June 30, 2023 | 27.39M |
| March 31, 2023 | 52.10M |
| Date | Value |
|---|---|
| December 31, 2022 | 21.32M |
| September 30, 2022 | 19.68M |
| June 30, 2022 | 26.41M |
| March 31, 2022 | 24.54M |
| December 31, 2021 | 20.88M |
| September 30, 2021 | 12.68M |
| June 30, 2021 | 11.78M |
| March 31, 2021 | 12.42M |
| December 31, 2020 | 16.63M |
| September 30, 2020 | 9.913M |
| June 30, 2020 | 12.50M |
| March 31, 2020 | 4.173M |
| December 31, 2019 | 3.802M |
| September 30, 2019 | 5.276M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Climb Bio, Inc. | 10.85M |
| MapLight Therapeutics, Inc. | 53.44M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |